Kiora Pharmaceuticals (NASDAQ:KPRX) Lifted to Strong-Buy at Maxim Group

Maxim Group upgraded shares of Kiora Pharmaceuticals (NASDAQ:KPRXFree Report) to a strong-buy rating in a report published on Thursday morning, reports.

Separately, HC Wainwright reiterated a buy rating and set a $18.00 price target on shares of Kiora Pharmaceuticals in a research report on Monday, May 20th.

Check Out Our Latest Analysis on Kiora Pharmaceuticals

Kiora Pharmaceuticals Trading Up 10.7 %

Shares of NASDAQ:KPRX opened at $5.36 on Thursday. Kiora Pharmaceuticals has a fifty-two week low of $3.60 and a fifty-two week high of $8.98. The company’s 50-day moving average price is $5.47 and its 200 day moving average price is $5.42.

Kiora Pharmaceuticals (NASDAQ:KPRXGet Free Report) last issued its quarterly earnings data on Friday, May 10th. The company reported $3.42 earnings per share (EPS) for the quarter, missing the consensus estimate of $5.58 by ($2.16). The firm had revenue of $16.00 million during the quarter, compared to analyst estimates of $16.00 million. As a group, research analysts forecast that Kiora Pharmaceuticals will post 0.99 EPS for the current year.

Insider Transactions at Kiora Pharmaceuticals

In other news, Director Erin Parsons purchased 5,260 shares of the firm’s stock in a transaction on Thursday, June 13th. The stock was purchased at an average cost of $4.88 per share, with a total value of $25,668.80. Following the purchase, the director now owns 5,260 shares in the company, valued at approximately $25,668.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In the last three months, insiders purchased 9,791 shares of company stock valued at $48,764. Company insiders own 0.94% of the company’s stock.

Hedge Funds Weigh In On Kiora Pharmaceuticals

An institutional investor recently bought a new position in Kiora Pharmaceuticals stock. Rosalind Advisors Inc. purchased a new stake in Kiora Pharmaceuticals, Inc. (NASDAQ:KPRXFree Report) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 2,300,000 shares of the company’s stock, valued at approximately $1,624,000. Kiora Pharmaceuticals makes up about 1.5% of Rosalind Advisors Inc.’s portfolio, making the stock its 22nd biggest position. Rosalind Advisors Inc. owned approximately 8.76% of Kiora Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission. 76.97% of the stock is currently owned by institutional investors and hedge funds.

Kiora Pharmaceuticals Company Profile

(Get Free Report)

Kiora Pharmaceuticals, Inc, a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases.

Featured Stories

Receive News & Ratings for Kiora Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiora Pharmaceuticals and related companies with's FREE daily email newsletter.